Literature DB >> 15913486

Prevention of cardiovascular events and diabetes with angiotensin-receptor blockers in hypertension: LIFE, SCOPE, and VALUE.

Sverre E Kjeldsen1, Arne S Westheim, Ingrid Os.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15913486     DOI： 10.1007/s11906-005-0001-8

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  9 in total

1.  Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation.

Authors:  S E Kjeldsen; S Julius; H Brunner; L Hansson; M Henis; S Ekman; J Laragh; G McInnes; B Smith; M Weber; A Zanchetti
Journal:  Blood Press       Date:  2001       Impact factor: 2.835

2.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

3.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

4.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.

Authors:  Hans Lithell; Lennart Hansson; Ingmar Skoog; Dag Elmfeldt; Albert Hofman; Bertil Olofsson; Peter Trenkwalder; Alberto Zanchetti
Journal:  J Hypertens       Date:  2003-05       Impact factor: 4.844

5.  Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.

Authors:  Sverre E Kjeldsen; Björn Dahlöf; Richard B Devereux; Stevo Julius; Peter Aurup; Jonathan Edelman; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven Snapinn; Hans Wedel
Journal:  JAMA       Date:  2002-09-25       Impact factor: 56.272

6.  Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.

Authors:  Michael A Weber; Stevo Julius; Sverre E Kjeldsen; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John H Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; M Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

7.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

8.  The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.

Authors:  J Mann; S Julius
Journal:  Blood Press       Date:  1998-05       Impact factor: 2.835

9.  Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.

Authors:  Lars H Lindholm; Hans Ibsen; Knut Borch-Johnsen; Michael Hecht Olsen; Kristian Wachtell; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan M Edelman; Steven Snapinn
Journal:  J Hypertens       Date:  2002-09       Impact factor: 4.844
  9 in total
  1 in total

Review 1.  Intracrine angiotensin II functions originate from noncanonical pathways in the human heart.

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Jasmina Varagic; Che Ping Cheng; Leanne Groban; Hao Wang; James F Collawn; Louis J Dell Italia
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-27       Impact factor: 4.733
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.